Benzodiazepine use in medical cannabis authorization adult patients from 2013 to 2021: Alberta, Canada
Abstract Background: Benzodiazepines are a class of medications that are being frequently prescribed in Canada but carry significant risk of…
Jason R. B. Dyck
Chemical Composition of Commercial Cannabis
Abstract Cannabis is widely used for medicinal and recreational purposes. As a result, there is increased interest in its chemical…
Metabolomic Fingerprint of Behavioral Changes in Response to Full-Spectrum Cannabis Extracts
Abstract Numerous existing full-spectrum cannabis extract products have been used in clinical trials for the treatment of various diseases. Despite…
Substance Use Disorders and Psychoactive Drug Poisoning in Medically Authorized Cannabis Patients: Longitudinal Cohort Study
Abstract Objectives: Poisoning from psychoactive drugs and substance use disorders (SUD) have been reported among non-medical cannabis users. However, little…
Medical cannabis authorization and the risk of cardiovascular events: a longitudinal cohort study
Abstract Background: Cannabis is increasingly used for therapeutic purpose. However, its safety profile is not well known. This study assessed…
Gaps in evidence for the use of medically authorized cannabis: Ontario and Alberta, Canada
Abstract Background: With legal access to medical cannabis in Canada since 2001, there is a need to fully characterize its…
Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada
Abstract Background: The opioid overdose epidemic in Canada and the United States has become a public health crisis – with…
Cohort study of medical cannabis authorization and motor vehicle crash-related healthcare visits in 2014–2017 in Ontario, Canada
Abstract Background: With increasing numbers of countries/jurisdictions legalizing cannabis, cannabis impaired driving has become a serious public health concern. Despite…